← Leaderboards
Michael J Garabedian
New York University School Of Medicine
$7,578,313
Attributed
$11,648,847
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,648,847 · 11
By mechanism
R01$8,440,807 · 5
R21$2,201,188 · 5
R56$1,006,852 · 1
Top collaborators
- Moses Victor Chao8 shared
- Edward A Fisher4 shared
- Kent W Kirshenbaum4 shared
- Ryan Comfort Branski2 shared
- Bo Shopsin2 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Martin Joseph Sadowski$14,045,716
- Ryan Comfort Branski$7,514,357
- Ryosuke Nakamura$466,125
Others in their field
Top investigators on “Genetic Transcription”
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$69,905,031
- Bing Ren · Ludwig Institute For Cancer Research$61,600,123
- Richard M Myers · Hudson-Alpha Institute For Biotechnology$54,253,356
- Richard Gibbs · Baylor College Of Medicine$53,550,246
- John A Tainer · Scripps Research Institute$51,251,962
- Deepak Srivastava · J. David Gladstone Institutes$50,027,907
Research focus
Genetic TranscriptionIn VivoMediatingResponseCellsPhosphorylationGene ExpressionAffectGenesSerineInsightGlucocorticoidsMolecularPathway InteractionsBindingRegulationSignal TransductionProteinsReceptorTranscription FactorPublishingGlucocorticoid ReceptorGene Expression RegulationBase
Grant awards (31)
Peptoid conjugates targeting prostate cancer$575,698
R01 · FY2025 · CA · contact PI
Peptoid conjugates targeting prostate cancer$624,001
R01 · FY2024 · CA · contact PI
Molecular mechanisms underlying optimal glucocorticoid therapy for vocal fold disease$211,875
R21 · FY2024 · DC · contact PI
âProtection from MRSA lethality by inhibiting LXRα phosphorylationâ$211,875
R21 · FY2024 · AI · contact PI
Molecular mechanisms underlying optimal glucocorticoid therapy for vocal fold disease$254,250
R21 · FY2023 · DC · contact PI
âProtection from MRSA lethality by inhibiting LXRα phosphorylationâ$254,250
R21 · FY2023 · AI · contact PI
Attenuation of neuroinflammation and Alzheimerâs disease pathology by disrupting LXRα phosphorylation$211,875
R21 · FY2022 · AG · contact PI
Attenuation of neuroinflammation and Alzheimerâs disease pathology by disrupting LXRα phosphorylation$254,250
R21 · FY2021 · AG · contact PI
Glucocorticoid receptor phosphorylation in endocrine adaptation to stress$495,420
R56 · FY2020 · MH · contact PI
Peptoid conjugates as inhibitors of androgen receptor dimerization and function in enzalutamide-resistant prostate cancer$180,449
R21 · FY2020 · CA · contact PI
Glucocorticoid receptor phosphorylation in endocrine adaptation to stress$511,432
R56 · FY2019 · MH · contact PI
Peptoid conjugates as inhibitors of androgen receptor dimerization and function in enzalutamide-resistant prostate cancer$216,835
R21 · FY2019 · CA · contact PI
Regulation of LXR alpha by glucose & cholesterol in diabetes & atherosclerosis$504,906
R01 · FY2017 · HL · contact PI
Targeting the glucocorticoid receptor in enzalutamide resistant prostate cancer$221,198
R21 · FY2017 · CA · contact PI
Regulation of LXR alpha by glucose & cholesterol in diabetes & atherosclerosis$520,698
R01 · FY2016 · HL · contact PI
Targeting the glucocorticoid receptor in enzalutamide resistant prostate cancer$184,331
R21 · FY2016 · CA · contact PI
Regulation of LXR alpha by glucose & cholesterol in diabetes & atherosclerosis$512,887
R01 · FY2015 · HL
Regulation of LXR alpha by glucose & cholesterol in diabetes & atherosclerosis$538,073
R01 · FY2014 · HL
Mechanisms of BDNF and Glucocorticoid Action$488,928
R01 · FY2013 · MH
Mechanisms of BDNF and Glucocorticoid Action$488,927
R01 · FY2013 · MH
Mechanisms of BDNF and Glucocorticoid Action$511,507
R01 · FY2012 · MH
Mechanisms of BDNF and Glucocorticoid Action$526,854
R01 · FY2011 · MH
Mechanisms of BDNF and Glucocorticoid Action$516,672
R01 · FY2010 · MH
Mechanisms of BDNF and Glucocorticoid Action$536,258
R01 · FY2009 · MH
REGULATION OF ANDROGEN RECEPTOR ACTIVITY IN THE PROSTATE$301,025
R01 · FY2003 · DK
REGULATION OF GLUCOCORTICOID RECEPTOR BY PHOSPHORYLATION$334,978
R01 · FY2002 · DK
REGULATION OF ANDROGEN RECEPTOR ACTIVITY IN THE PROSTATE$291,940
R01 · FY2002 · DK
REGULATION OF GLUCOCORTICOID RECEPTOR BY PHOSPHORYLATION$325,294
R01 · FY2001 · DK
REGULATION OF ANDROGEN RECEPTOR ACTIVITY IN THE PROSTATE$283,129
R01 · FY2001 · DK
REGULATION OF GLUCOCORTICOID RECEPTOR BY PHOSPHORYLATION$291,402
R01 · FY2000 · DK
REGULATION OF ANDROGEN RECEPTOR ACTIVITY IN THE PROSTATE$267,630
R01 · FY2000 · DK